What we do ?
DemeRx is a clinical stage drug development company advancing a new chemical entity for the treatment of alcohol use disorder
Imagine a World Without Alcohol and Drug Addiction
Alcohol abuse has grave consequences on our society
The misuse of alcohol disrupts families, shreds social fabric, often leads to job and income loss, contributes to poor school and work performance, and is often a causal factor in domestic violence and auto accidents. The consequences of alcohol abuse for children in society are especially tragic.
Addiction is a family disease.
Ibogaine and Noribogaine
Product Candidates
Learn about target product profiles of Ibogaine and Noribogaine.
Learn More
DemeRx
Who we are
DemeRx is a clinical stage drug development company advancing a new chemical entity for the treatment of Alcohol Use Disorder. Read more at
Our Team
Meet
Our Experts
Learn more about our management team, board of directors, and scientific advisors who are leading the effort to tackle opioid addiction. Read more.
View All
Effective Solutions
Solutions in Development
Preventing relapse and easing protracted alcohol withdrawal symptoms for people in early recovery
DemeRx is advancing clinical trials to demonstrate that a daily dose of noribogaine can mitigate the complicated and unpleasant symptoms of withdrawal and cravings, making recovery more achievable.
Noribogaine (DMX-1001)
A new molecule in the class of neuroplastogens and a lead molecule for next generation drug products.
Potential opportunity to treat alcoholism and other addictive disorders.
Targets multiple transporter and receptor sites in brain relevant to craving, mood and protracted withdrawal symptoms that
trigger relapse.
Reduces self-administration of alcohol, opioids, cocaine and nicotine in rodent models of addiction.
Treatment of alcohol use disorder in early abstinence is needed to prevent relapse. Medication development for the treatment of alcohol use disorder is an unmet need.
DemeRx's solution to alcoholism
DemeRx is evaluating the safety and pharmacokinetics of noribogaine in normal healthy volunteers to advance studies in patients with alcohol use disorder.
Noribogaine for alcohol use disorder
DemeRx will announce topline results from a multiple ascending dose study in Q1 2025. Next steps in clinical development are regulatory approvals of clinical trials of noribogaine for relapse prevention in treating alcohol use disorder.
